Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
veldoreotide-conjugated quantum dots
- Development stage
- Unknown
- Lead developer
- Al-Azhar University
- Modality
- Nanoparticles → Drug Delivery Systems, Peptides
- Administration
- Topical
01
Overview
Veldoreotide-conjugated quantum dots is an experimental theranostic agent developed by Al-Azhar University for the topical treatment and bioimaging of breast cancer. The formulation consists of veldoreotide, a somatostatin receptor (SSTR) agonist, conjugated to CdS/ZnS core-shell quantum dots with carboxylic acid functionalization (QDs-COOH). Delivered as a topical cream using emulsion technology, the agent is designed for deep deposition into breast tissue. Veldoreotide serves as a targeting ligand for SSTRs on cancer cells, while the quantum dots provide both therapeutic anti-cancer activity and fluorescent properties for diagnostic imaging. This approach aims to localize treatment and minimize systemic exposure.
- Other names
- Quantum dots coated with veldoreotideVELD-QDsFluorescent Nanoparticles Conjugated Long-acting Somatostatin Analog
02
Targets
SSTR2 (Somatostatin receptor type 2)SSTR5 (Somatostatin receptor 5)SSTR4 (Somatostatin receptor 4)
Beyond the preview
Go deeper on veldoreotide-conjugated quantum dots.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on veldoreotide-conjugated quantum dots.